- Home
- ALLK vs ME Comparison
ALLK vs ME Comparison
Compare ALLK & ME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLK
- ME
- Stock Information
- Founded
- ALLK 2012
- ME 2006
- Country
- ALLK United States
- ME United States
- Employees
- ALLK N/A
- ME N/A
- Industry
- ALLK Biotechnology: Pharmaceutical Preparations
- ME Precision Instruments
- Sector
- ALLK Health Care
- ME Health Care
- Exchange
- ALLK Nasdaq
- ME Nasdaq
- Market Cap
- ALLK 22.5M
- ME 98.7M
- IPO Year
- ALLK 2018
- ME N/A
- Fundamental
- Price
- ALLK $0.25
- ME $2.75
- Analyst Decision
- ALLK Hold
- ME Hold
- Analyst Count
- ALLK 3
- ME 1
- Target Price
- ALLK $2.00
- ME $9.40
- AVG Volume (30 Days)
- ALLK 4.8M
- ME 184.9K
- Earning Date
- ALLK 03-13-2025
- ME 01-28-2025
- Dividend Yield
- ALLK N/A
- ME N/A
- EPS Growth
- ALLK N/A
- ME N/A
- EPS
- ALLK N/A
- ME N/A
- Revenue
- ALLK N/A
- ME $208,775,000.00
- Revenue This Year
- ALLK N/A
- ME $21.93
- Revenue Next Year
- ALLK N/A
- ME $17.31
- P/E Ratio
- ALLK N/A
- ME N/A
- Revenue Growth
- ALLK N/A
- ME N/A
- 52 Week Low
- ALLK $0.23
- ME $2.66
- 52 Week High
- ALLK $1.69
- ME $16.52
- Technical
- Relative Strength Index (RSI)
- ALLK 28.77
- ME 30.98
- Support Level
- ALLK $0.23
- ME $3.25
- Resistance Level
- ALLK $0.26
- ME $3.58
- Average True Range (ATR)
- ALLK 0.11
- ME 0.25
- MACD
- ALLK -0.08
- ME -0.06
- Stochastic Oscillator
- ALLK 1.62
- ME 0.91
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.